Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita

被引:52
|
作者
Sesarman, Alina [2 ]
Sitaru, Ana Gabriela
Olaru, Florina [2 ]
Zillikens, Detlef [2 ]
Sitaru, Cassian [1 ,2 ,3 ]
机构
[1] Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany
[2] Univ Lubeck, Dept Dermatol, Lubeck, Germany
[3] Univ Lubeck, Inst Med Microbiol & Hyg, Lubeck, Germany
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2008年 / 86卷 / 08期
关键词
autoantibodies; epidermolysis bullosa acquisita; extracellular matrix; inflammation;
D O I
10.1007/s00109-008-0366-7
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disease caused by autoantibodies against type VII collagen. The neonatal Fc receptor (FcRn) regulates immunoglobulin G (IgG) homeostasis and thus controls serum levels of antibodies. In this study, we investigated the effects of FcRn deficiency on the levels of autoantibodies against type VII collagen and blistering in EBA. For this purpose, rabbit IgG against murine type VII collagen was injected into FcRn-deficient and wild-type (n = 10 per group) mice. Enzyme-linked immunosorbent assay levels of serum IgG against type VII collagen were significantly lower in mutant compared with wild-type mice. Analysis of serum levels of specific autoantibodies induced in FcRn-deficient and wild-type mice (n = 10 per group) by immunization with type VII collagen showed significantly lower serum levels of IgG against type VII collagen in FcRn-deficient mice compared with wild-type animals. Importantly, the extent of blistering disease after injection of IgG against type VII collagen was significantly reduced in FcRn-deficient mice compared to wild-type controls. Our data demonstrate that FcRn maintains levels of pathogenic autoantibodies and thereby promotes tissue injury in experimental EBA. Therefore, modulation of FcRn function using inhibitors may reduce pathogenic IgG levels, offering therapeutic benefit in patients with antibody-mediated diseases.
引用
收藏
页码:951 / 959
页数:9
相关论文
共 50 条
  • [21] The role of the Syk tyrosine kinase in the development of experimental epidermolysis bullosa acquisita
    Nemeth, T.
    Virtic, O.
    Sitaru, C.
    Mocsai, A.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 54 - 54
  • [22] Phospholipase Cγ2 Is Essential for Experimental Models of Epidermolysis Bullosa Acquisita
    Szilveszter, Kata P.
    Vikar, Simon
    Horvath, Adam, I
    Helyes, Zsuzsanna
    Sardy, Miklos
    Mocsai, Attila
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (04) : 1114 - 1125
  • [23] Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita
    Gross, Natalie
    Marketon, Jana
    Mousavi, Sadegh
    Kalies, Kathrin
    Ludwig, Ralf J.
    Bieber, Katja
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [24] FcgammaRIV is crucial for neutrophil effector function in experimental epidermolysis bullosa acquisita
    Kasperkiewicz, M.
    Wende, S.
    Nimmerjahn, F.
    Hirose, M.
    Iwata, H.
    Kalies, K.
    Schmidt, E.
    Westermann, J.
    Koehl, J.
    Zillikens, D.
    Ludwig, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 : S9 - S9
  • [25] T cells are required for initiation of autoimmunity in experimental epidermolysis bullosa acquisita
    Sitaru, C.
    Sesarman, A.
    Zillikens, D.
    Solbach, W.
    Hultman, P.
    Sitaru, G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 : S5 - S5
  • [27] T cells are required for initiation of autoimmunity in experimental epidermolysis bullosa acquisita
    Sitaru, C.
    Sesarman, A.
    Zillikens, D.
    Solbach, W.
    Hultman, P.
    Sitaru, A. G.
    EXPERIMENTAL DERMATOLOGY, 2008, 17 (03) : 252 - 252
  • [28] Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options
    Kasperkiewicz, Michael
    Sadik, Christian D.
    Bieber, Katja
    Ibrahim, Saleh M.
    Manz, Rudolf A.
    Schmidt, Enno
    Zillikens, Detlef
    Ludwig, Ralf J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (01) : 24 - 33
  • [29] EPIDERMOLYSIS BULLOSA-ACQUISITA - IMMUNOHISTOCHEMICAL AND ULTRASTRUCTURAL FINDINGS IN CUTANEOUS AND GASTROINTESTINAL TISSUE
    RAY, TL
    LEVINE, J
    WEISS, W
    WARD, PA
    CLINICAL RESEARCH, 1980, 28 (02): : A580 - A580
  • [30] Epidermolysis bullosa acquisita treated with basiliximab, an interleukin-2 receptor antibody
    Haufs, MG
    Haneke, E
    ACTA DERMATO-VENEREOLOGICA, 2001, 81 (01) : 72 - 72